Unfortunately, nuts, it's not the "layperson" who needs to be informed.
And the oncologists are quite capable of interpreting the data for themselves and will not be confused between the terms median and average.
And it is them who will determine the sales of Provenge, like it or not - it's less of a PR exercise than you might like to think.
And that's says nothing about the re-imbursement issues......
learning curve, page-3
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 34.5¢ | 35.0¢ | 33.5¢ | $724.1K | 2.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 60483 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 55452 | 4 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |